Tag: renal-cell carcinoma

Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally advanced or metastatic clear cell ...

1. No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib monotherapy groups. 2. Serious adverse events ...

1. Median PFS (5.6 months vs 5.6 months) and median OS (21.4 months vs 18.1 months) were similar in both ...

Click here to read this study in NEJM.  ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...

1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...

1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...

1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring placebo ...

1. This prospective study found that the Systematic Inflammatory Response Index (SIRI) and Systemic Immune-Inflammation Index (SII), as well as ...

1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events ...

Click to read the study in The Lancet ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...